Compare GVH & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GVH | GDTC |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | Australia | Singapore |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5M | 12.4M |
| IPO Year | 2023 | 2021 |
| Metric | GVH | GDTC |
|---|---|---|
| Price | $4.75 | $0.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $80.00 | N/A |
| AVG Volume (30 Days) | ★ 643.2K | 22.3K |
| Earning Date | 02-17-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $102,768.97 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.03 | $0.68 |
| 52 Week High | $10.74 | $3.68 |
| Indicator | GVH | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 54.26 | 41.35 |
| Support Level | $4.34 | $0.93 |
| Resistance Level | $4.90 | $1.09 |
| Average True Range (ATR) | 0.61 | 0.09 |
| MACD | 0.11 | -0.02 |
| Stochastic Oscillator | 52.34 | 21.64 |
Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.